Purple Biotech
PPBT
13 hedge funds and large institutions have $141K invested in Purple Biotech in 2026 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 7 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
2.93% less ownership
Funds ownership: 8.14% → 5.21% (-2.9%)
13% less funds holding
Funds holding: 15 → 13 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
54% less capital invested
Capital invested by funds: $306K → $141K (-$165K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$49.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$44.4K |
| 3 |
IAA
Independent Advisor Alliance
Charlotte,
North Carolina
|
+$40.1K |
| 4 |
SP
SmartHarvest Portfolios
Poulsbo,
Washington
|
+$34.9K |
| 5 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$4.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$137K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.91K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$2.01K |
| 4 |
Morgan Stanley
New York
|
-$1.28K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
-$436 |
PPBT Hedge Fund Activity: Q2 2026 in Review
13 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q2 2026, worth a combined $141K — down 54% from $306K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PPBT and 5 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was HRT Financial, opening a new position worth an estimated $49.4K. The largest seller was Susquehanna International Group, cutting an estimated $137K.
- 13 institutional investors held Purple Biotech (PPBT) as of Q2 2026, down from 15 in Q1 2026.
- Funds reported $141K of Purple Biotech stock for Q2 2026, down 54% quarter-over-quarter.
- 5 funds opened new Purple Biotech positions in Q2 2026 and 7 closed out, a net change of -2 holders.
- The largest Purple Biotech buyer in Q2 2026 was HRT Financial, an estimated $49.4K added.
- The largest Purple Biotech seller in Q2 2026 was Susquehanna International Group, an estimated $137K sold.
Based on aggregated 13F filings for Q2 2026.